Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Horm Metab Res. 2012 Apr;44(4):312-8. doi: 10.1055/s-0032-1304563. Epub 2012 Feb 20.
Although the α-glucosidase inhibitor miglitol (MG) has been reported to have anorexigenic effects, the mechanism remains to be elucidated. The objective of this study was to explore the effects of MG on appetite in relation to concomitant changes in postprandial gut hormone levels. This randomized open-label crossover study included 20 healthy volunteers. The effects of 50 mg MG on glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and ghrelin levels were assessed in conjunction with a simultaneous determination of appetite scores using visual analogue scales (VAS) over 3 h after the ingestion of a 592 kcal test cookie. Additionally, the gastric emptying rate (GER) was measured using breath ¹³CO₂ appearance in 10 subjects. 12 subjects were administered 50 mg MG thrice a day for 1 week, and alterations of the gut hormone levels and the VAS scores for appetite were evaluated. MG pre-administration resulted in a significant enhancement of GLP-1 and PYY responses induced by the cookie ingestion. Following MG administration, ghrelin level declined at 1 h, with a persistent suppression during the postprandial phase in contrast to the restoration to the basal level without MG. Furthermore, MG pre-administration suppressed appetite and maintained satiety evaluated using a VAS rating with concomitant inhibition of GER after cookie ingestion. One-week administration of MG did not influence either gut hormone levels before a meal or VAS rating during a whole day. These observations suggest that MG exerts an anorexigenic effects with concomitant alterations of gut hormone secretions and gastric emptying after meal ingestion.
尽管 α-葡萄糖苷酶抑制剂米格列醇（MG）已被报道具有抑制食欲的作用，但作用机制仍有待阐明。本研究旨在探讨 MG 对食欲的影响及其与餐后肠道激素水平变化的关系。该随机、开放标签交叉研究纳入了 20 名健康志愿者。在摄入 592 千卡测试饼干后 3 小时内，通过视觉模拟量表（VAS）同时评估食欲评分，评估 50mg MG 对胰高血糖素样肽-1（GLP-1）、肽 YY（PYY）和胃饥饿素水平的影响。此外，在 10 名受试者中使用呼气 ¹³CO₂ 出现率测量胃排空率（GER）。12 名受试者每日口服 MG 50mg 三次，持续 1 周，评估肠道激素水平和 VAS 评分的变化。MG 给药前可显著增强饼干摄入引起的 GLP-1 和 PYY 反应。MG 给药后，1 小时时胃饥饿素水平下降，与无 MG 时餐后阶段持续抑制相比，恢复到基础水平。此外，MG 给药前可抑制食欲并维持饱腹感，通过 VAS 评分进行评估，同时抑制饼干摄入后的 GER。MG 给药 1 周不会影响餐前肠道激素水平或全天 VAS 评分。这些观察结果表明，MG 在餐后摄入时通过改变肠道激素分泌和胃排空来发挥抑制食欲的作用。
